{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:02:07Z","timestamp":1784523727153,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>On conventional magnetic resonance imaging, pseudoprogression after radiotherapy for high-grade glioma may closely resemble true tumor progression, leading to unnecessary surgery, premature treatment escalation, or delayed appropriate therapy. We developed and internally validated an exploratory multivariable model for individualized pseudoprogression risk estimation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort included 222 patients with World Health Organization 2021 central nervous system grade 3 or 4 glioma who underwent surgery followed by radiotherapy at Liuzhou Workers\u2019 Hospital from January 2015 to December 2024. Pseudoprogression was adjudicated before modeling through multidisciplinary review; 13 pseudoprogression cases had histopathological confirmation, and non-histologically confirmed cases required at least 6 months of stable or improved follow-up imaging. The complete two-reader radiomics matrix was analyzed using a strict split-first workflow. Dataset partitioning preceded ICC filtering, Z-score normalization, and LASSO modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3,404 radiomic features were analyzed. After reproducibility filtering and LASSO selection, 17 radiomic features were retained to construct the locked RadScore. In the held-out validation cohort, the integrated model combining RadScore, rCBV, ADC, NLR, MGMT promoter methylation, and TMZ treatment achieved an AUC of 0.811 (95% CI: 0.696-0.925). The clinical-imaging model without RadScore achieved a validation AUC of 0.744 (95% CI: 0.614-0.873), whereas RadScore alone achieved an AUC of 0.771 (95% CI: 0.648-0.894).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The integrated model showed acceptable internal validation performance and provided a clinically interpretable framework for individualized PsP risk estimation by combining radiomic, perfusion-diffusion, inflammatory, molecular, and treatment-related information. External validation with standardized imaging protocols is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1892760","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:21:07Z","timestamp":1784521267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiomics and clinical data predict pseudoprogression after radiotherapy in high-grade glioma"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiang","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]},{"name":"Guangxi Key Laboratory of Intelligent Radiotherapy and Translational Research for Malignant Tumors","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Danmeng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]},{"name":"Guangxi Key Laboratory of Intelligent Radiotherapy and Translational Research for Malignant Tumors","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]},{"name":"Guangxi Key Laboratory of Intelligent Radiotherapy and Translational Research for Malignant Tumors","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhuohua","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]},{"name":"Guangxi Key Laboratory of Intelligent Radiotherapy and Translational Research for Malignant Tumors","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Mingjing","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]},{"name":"Guangxi Key Laboratory of Intelligent Radiotherapy and Translational Research for Malignant Tumors","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University","place":["Liuzhou, China"]},{"name":"Guangxi Key Laboratory of Intelligent Radiotherapy and Translational Research for Malignant Tumors","place":["Liuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox149","article-title":"Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location","volume":"20","author":"Karremann","year":"2018","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-023-01234-2","article-title":"Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme","volume":"38","author":"Mekala","year":"2023","journal-title":"Metab Brain Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100779","article-title":"Myeloperoxidase exerts anti-tumor activity in glioma after radiotherapy","volume":"26","author":"Ali","year":"2022","journal-title":"Neoplasia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/RCT.0000000000001716","article-title":"Dynamic contrast-enhanced MRI processing comparison for distinguishing true progression from pseudoprogression in high-grade glioma","volume":"49","author":"Amer","year":"2025","journal-title":"J Comput Assist Tomogr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020285","article-title":"Pseudoprogression in glioblastoma: Role of metabolic and functional MRI-systematic review","volume":"10","author":"Sidibe","year":"2022","journal-title":"Biomedicines"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12047","article-title":"Pseudoprogression in high-grade glioma","volume":"196","author":"Knudsen-Baas","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00062-017-0584-x","article-title":"Incidence of tumour progression and pseudoprogression in high-grade gliomas: A systematic review and meta-analysis","volume":"28","author":"Abbasi","year":"2018","journal-title":"Clin Neuroradiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051342","article-title":"Hemodynamic imaging in cerebral diffuse glioma-part B: Molecular correlates, treatment effect monitoring, prognosis, and future directions","volume":"14","author":"Stumpo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: Update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s12885-021-08414-2","article-title":"Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas","volume":"21","author":"Moon","year":"2021","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11912-021-01020-2","article-title":"Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of Malignant brain tumors","volume":"23","author":"Overcast","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/RCT.0000000000001543","article-title":"Dynamic susceptibility contrast-enhanced perfusion-weighted imaging in differentiation between recurrence and pseudoprogression in high-grade glioma: A meta-analysis","volume":"48","author":"Gu","year":"2024","journal-title":"J Comput Assist Tomogr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13058-023-01688-3","article-title":"Machine learning radiomics of magnetic resonance imaging predicts recurrence-free survival after surgery and correlation of LncRNAs in patients with breast cancer: A multicenter cohort study","volume":"25","author":"Yu","year":"2023","journal-title":"Breast Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.865171","article-title":"Preoperative diagnosis and molecular characterization of gliomas with liquid biopsy and radiogenomics","volume":"13","author":"Balana","year":"2022","journal-title":"Front Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.27954","article-title":"An update in imaging evaluation of histopathological grade of soft tissue sarcomas using structural and quantitative imaging and radiomics","volume":"55","author":"Fang","year":"2022","journal-title":"J Magn Reson Imaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.04.002","article-title":"Radiomics in breast cancer classification and prediction","volume":"72","author":"Conti","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41698-021-00205-z","article-title":"Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients","volume":"5","author":"Yan","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2025.112508","article-title":"Multi-sequence MRI radiomics model for discrimination of recurrence and pseudoprogression in gliomas","volume":"194","author":"Li","year":"2025","journal-title":"Eur J Radiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2024.03.019","article-title":"Imaging and liquid biopsy for distinguishing true progression from pseudoprogression in gliomas, current advances and challenges","volume":"31","author":"Li","year":"2024","journal-title":"Acad Radiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123835","article-title":"FET PET radiomics for differentiating pseudoprogression from early tumor progression in glioma patients post-chemoradiation","volume":"12","author":"Lohmann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071778","article-title":"Radiomics and radiogenomics in differentiating progression, pseudoprogression, and radiation necrosis in gliomas","volume":"13","author":"Reddy","year":"2025","journal-title":"Biomedicines"},{"key":"B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jneumeth.2016.03.001","article-title":"The first step for neuroimaging data analysis: DICOM to NIfTI conversion","volume":"264","author":"Li","year":"2016","journal-title":"J Neurosci Methods"},{"key":"B25","doi-asserted-by":"publisher","first-page":"10826","DOI":"10.1038\/s41598-022-14983-4","article-title":"A general skull stripping of multiparametric brain MRIs using 3D convolutional neural network","volume":"12","author":"Pei","year":"2022","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscychresns.2023.111595","article-title":"Spatial normalization discrepancies between native and MNI152 brain template scans in gamma ventral capsulotomy patients","volume":"329","author":"Giff","year":"2023","journal-title":"Psychiatry Res Neuroimaging"},{"key":"B27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12021-024-09655-9","article-title":"DeepN4: Learning N4ITK bias field correction for T1-weighted images","volume":"22","author":"Kanakaraj","year":"2024","journal-title":"Neuroinformatics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1109\/TMI.2010.2046908","article-title":"N4ITK: Improved N3 bias correction","volume":"29","author":"Tustison","year":"2010","journal-title":"IEEE Trans Med Imaging"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jon.12129","article-title":"Normalization of white matter intensity on T1-weighted images of patients with acquired central nervous system demyelination","volume":"25","author":"Ghassemi","year":"2015","journal-title":"J Neuroimaging"},{"key":"B30","doi-asserted-by":"publisher","first-page":"110424","DOI":"10.1016\/j.mri.2025.110424","article-title":"Harmonized connectome resampling for variance in voxel sizes","volume":"121","author":"McMaster","year":"2025","journal-title":"Magn Reson Imaging"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5091218","article-title":"Synthetic apparent diffusion coefficient for high b-value diffusion-weighted MRI in prostate","volume":"2020","author":"Sahoo","year":"2020","journal-title":"Prostate Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18383\/j.tom.2016.00172","article-title":"Dynamic susceptibility contrast-MRI quantification software tool: Development and evaluation","volume":"2","author":"Korfiatis","year":"2016","journal-title":"Tomography"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103230","article-title":"Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - radiological features and metric markers","volume":"159","author":"Le Fevre","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab044","article-title":"Combined 18F-FET PET and diffusion kurtosis MRI in posttreatment glioblastoma: Differentiation of true progression from treatment-related changes","volume":"3","author":"D'Amore","year":"2021","journal-title":"Neuro-Oncol Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52306","article-title":"Radiomics in glioma: Emerging trends and challenges","volume":"12","author":"Wang","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2024.05.003","article-title":"The efficacy of using a multiparametric magnetic resonance imaging-based radiomics model to distinguish glioma recurrence from pseudoprogression","volume":"111","author":"Fu","year":"2024","journal-title":"Magn Reson Imaging"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160642","article-title":"Texture analysis of medical images for radiotherapy applications","volume":"90","author":"Scalco","year":"2017","journal-title":"Br J Radiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11060-017-2375-2","article-title":"Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape","volume":"134","author":"Ellingson","year":"2017","journal-title":"J Neuro-Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S202546","article-title":"Neutrophil-lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas","volume":"11","author":"Huang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018194","article-title":"The value of MGMT promoter methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis","volume":"98","author":"Zhou","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2016.10.004","article-title":"IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy","volume":"151","author":"Li","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s13042-022-01536-4","article-title":"Brain tumor segmentation based on region of interest-aided localization and segmentation U-Net","volume":"13","author":"Li","year":"2022","journal-title":"Int J Mach Learn Cybern"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab042","article-title":"MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: An international study","volume":"3","author":"Tam","year":"2021","journal-title":"Neuro-Oncol Adv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-021-08251-8","article-title":"Sources of variation in multicenter rectal MRI data and their effect on radiomics feature reproducibility","volume":"32","author":"Schurink","year":"2022","journal-title":"Eur Radiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7679","article-title":"Performance of intraclass correlation coefficient (ICC) as a reliability index under various distributions in scale reliability studies","volume":"37","author":"Mehta","year":"2018","journal-title":"Stat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the Lasso","volume":"58","author":"Tibshirani","year":"2018","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103188","article-title":"Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1 - molecular, morphological and clinical features","volume":"157","author":"Le Fevre","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11060-025-05299-0","article-title":"Clinical predictors of pseudoprogression in glioblastoma: A retrospective cohort analysis","volume":"176","author":"Hoosemans","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.21037\/atm.2019.11.121","article-title":"Overview of clinical prediction models","volume":"8","author":"Chen","year":"2020","journal-title":"Ann Transl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrai.2026.100074","article-title":"Explainable radiomics with probability calibration for postoperative glioblastoma surveillance","volume":"5","author":"Christodoulou","year":"2026","journal-title":"Eur J Radiol Artif Intell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1731258","article-title":"Explainable, modality-adaptive radiomics for MGMT methylation prediction in high-grade glioma: a decision-curve analysis study","volume":"15","author":"Christodoulou","year":"2026","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1892760\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:21:08Z","timestamp":1784521268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1892760\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":51,"alternative-id":["10.3389\/fonc.2026.1892760"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1892760","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"1892760"}}